Advertisement
Canada markets open in 8 hours 39 minutes

  • S&P/TSX

    21,788.48
    -60.11 (-0.28%)
     

  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     

  • DOW

    39,112.16
    -299.05 (-0.76%)
     

  • CAD/USD

    0.7323
    +0.0000 (+0.00%)
     

  • CRUDE OIL

    81.22
    +0.39 (+0.48%)
     

  • Bitcoin CAD

    84,346.78
    +718.59 (+0.86%)
     

  • CMC Crypto 200

    1,281.05
    +31.92 (+2.56%)
     

  • GOLD FUTURES

    2,328.10
    -2.70 (-0.12%)
     

  • RUSSELL 2000

    2,022.35
    -8.47 (-0.42%)
     

  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     

  • NASDAQ futures

    19,989.25
    +17.00 (+0.09%)
     

  • VOLATILITY

    12.84
    -0.49 (-3.68%)
     

  • FTSE

    8,247.79
    -33.76 (-0.41%)
     

  • NIKKEI 225

    39,674.59
    +501.44 (+1.28%)
     

  • CAD/EUR

    0.6834
    +0.0002 (+0.03%)
     

Karyopharm to Participate at the Jefferies Global Healthcare Conference

PR Newswire
·2 min read

NEWTON, Mass., May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Global Healthcare Conference in a fireside chat on Wednesday, June 5, 2024 at 1:00 p.m. ET in New York, NY.

(PRNewsfoto/Karyopharm Therapeutics Inc.)
(PRNewsfoto/Karyopharm Therapeutics Inc.)

A live webcast of the event, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

ADVERTISEMENT

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-jefferies-global-healthcare-conference-302158124.html

SOURCE Karyopharm Therapeutics Inc.